Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions

Pseudomonas aeruginosa biofilms limit the efficacy of currently available antibacterial therapies and pose significant clinical challenges. Pseudomonal biofilms are complicated further when other markers of persistence such as mucoid and hypermutable phenotypes are present. There is currently a pauc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2024-12
Main Authors: Kostoulias, Xenia, Fu, Ying, Morris, Faye C, Yu, Crystal, Qu, Yue, Chang, Christina C, Blakeway, Luke, Landersdorfer, Cornelia B, Abbott, Iain J, Wang, Lynn, Wisniewski, Jessica, Yu, Yunsong, Li, Jian, Peleg, Anton Y
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pseudomonas aeruginosa biofilms limit the efficacy of currently available antibacterial therapies and pose significant clinical challenges. Pseudomonal biofilms are complicated further when other markers of persistence such as mucoid and hypermutable phenotypes are present. There is currently a paucity of data regarding the activity of the newer β-lactam/β-lactamase inhibitor combination ceftolozane/tazobactam against P. aeruginosa biofilms. We evaluated the efficacy of ceftolozane/tazobactam against clinical P. aeruginosa isolates, the laboratory isolate PAO1 and its isogenic mutS-deficient hypermutator derivative (PAOMS) grown under static and dynamic biofilm conditions. The clinical isolate collection included strains with mucoid and hypermutable phenotypes. Ceftolozane/tazobactam exposure led to a bactericidal (≥3 log cfu/cm2) biofilm reduction in 15/18 (83%) clinical isolates grown under static conditions, irrespective of carbapenem susceptibility or mucoid phenotype, with greater activity compared with colistin (P 
ISSN:1460-2091
1460-2091
DOI:10.1093/jac/dkae413